DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced ... and survodutide (a drug with the same MOA), while also ...

The results suggest that Revita, the Company's novel approach to targeting gut dysfunction, a root cause of obesity, may help prevent weight regain after patients stop GLP-1 drugs-addressing ...

At an individual product level, the sale growth of Mounjaro was off the charts with 124% YoY growth ... Retatrutide is considered a next-generation weight loss drug, and Eli Lilly is expected ...

The Zacks Medical - Products industry is likely to face rising uncertainty amid tariff imposition by the United ...

Made in the USA, a new daily oral weight-loss pill from Eli Lilly won't require cold storage and is expected to hit markets ...

A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

Pfizer has ended its development of danuglipron, its oral weight-loss drug ... of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early ...

Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. The company said it halted development of danuglipron ...

Popular diabetes and weight loss drugs may do more than curb appetites — they may also help reduce the risk of dementia, according to new research. Two studies that noted this unexpected effect ...